Patents Assigned to RYVU THERAPEUTICS S.A.
  • Publication number: 20240009175
    Abstract: Substituted tetrazole derivatives are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
    Type: Application
    Filed: March 16, 2021
    Publication date: January 11, 2024
    Applicants: Merck Patent GmbH, RYVU THERAPEUTICS S.A.
    Inventors: Thomas FUCHSS, Lisa Koetzner, Christina Schindler, Daniel Kuhn
  • Publication number: 20230271956
    Abstract: Substituted amide derivatives are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
    Type: Application
    Filed: March 16, 2021
    Publication date: August 31, 2023
    Applicants: Merck Patent GmbH, RYVU THERAPEUTICS S.A.
    Inventors: Lisa Koetzner, Thomas Fuchss, Christina Schindler, Daniel Kuhn
  • Publication number: 20230149371
    Abstract: Substituted tetrazole derivatives are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
    Type: Application
    Filed: March 16, 2021
    Publication date: May 18, 2023
    Applicants: Merck Patent GmbH, RYVU THERAPEUTICS S.A.
    Inventors: Thomas FUCHSS, Lisa Koetzner, Christina Schindler, Daniel Kuhn
  • Patent number: 11613526
    Abstract: Compounds of the formula I in which R1 denotes A, Ar, Cyc, Het, COA or CN, R2 denotes SO2A, SOA, SA, SO2NHA, SO2NA2, S(?NH,?O)A, S(?NH)2A, NO2, Hal, CN, A, Het1, COOH or COOA, R3 denotes H or Hal, R4 denotes H or Hal, n denotes 1, 2 or 3, A denotes unbranched or branched alkyl having 1-6 C-atoms, Cyc denotes cyclic alkyl with 3 to 7 C-atoms, Ar denotes phenyl, Het denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, Het1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, and Hal denotes F, Cl, Br, or I, are inhibitors of HIF-2?, and can be employed for the treatment of diseases such as cancer.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: March 28, 2023
    Assignees: Merck Patent GmbH, RYVU THERAPEUTICS S.A.
    Inventors: Matthias Leiendecker, Hans-Peter Buchstaller
  • Publication number: 20230076506
    Abstract: The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.
    Type: Application
    Filed: December 11, 2020
    Publication date: March 9, 2023
    Applicant: RYVU THERAPEUTICS S.A.
    Inventors: Magdalena Izabela ZAWADZKA, Luigi Piero STASI, Maciej Krzysztof ROGACKI, Grzegorz Wojciech CWIERTNIA, Lukasz Piotr DUDEK, Agnieszka Justyna GIBAS, Anna RAJDA, Charles-Henry FABRITIUS, Adam RADZIMIERSKI, Tushar Ravindra MAHAJAN, Marcin Wojciech LES, Karol ZUCHOWICZ, Marek WRONOWSKI, David Jörg SYNAK, Sundara Raghuram TANGIRALA
  • Publication number: 20230055741
    Abstract: The present invention relates to compound-linker constructs and antibody-drug-conjugates of compounds of formula (I) that are useful as modulators of STING (Stimulator of Interferon Genes).
    Type: Application
    Filed: December 11, 2020
    Publication date: February 23, 2023
    Applicant: RYVU THERAPEUTICS S.A.
    Inventors: Magdalena Izabela ZAWADZKA, Luigi Piero STASI, Maciej Krzysztof ROGACKI, Grzegorz Wojciech CWIERTNIA, Lukasz Piotr DUDEK, Agnieszka Justyna GIBAS, Anna RAJDA, Charles-Henry FABRITIUS, Adam RADZIMIERSKI, Tushar Ravindra MAHAJAN, Marcin Wojciech LES, Karol ZUCHOWICZ, Marek WRONOWSKI, David Jörg SYNAK, Sundara Raghuram TANGIRALA
  • Publication number: 20230024721
    Abstract: Compounds of the formula I are inhibitors of HIF-2?, and can be employed for the treatment of diseases such as cancer.
    Type: Application
    Filed: November 24, 2020
    Publication date: January 26, 2023
    Applicants: Merck Patent GmbH, Ryvu Therapeutics S.A.
    Inventors: Matthias LEIENDECKER, Hans-Peter Buchstaller, Thomas Fuchss
  • Publication number: 20220402898
    Abstract: The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.
    Type: Application
    Filed: June 12, 2019
    Publication date: December 22, 2022
    Applicant: RYVU THERAPEUTICS S.A.
    Inventors: Monika Patrycja DOBRZANSKA, Magdalena Izabela ZAWADZKA, Adam RADZIMIERSKI, Grzegorz Witold TOPOLNICKI, Grzegorz Wojciech CWIERTNIA, Tushar Ravindra MAHAJAN, Charles-Henry FABRITIUS, Stefan CHMIELEWKSI, Karolina Maria GLUZA, Jose ALVAREZ, Maciej Krzysztof ROGACKI, Magdalena MROCZKOWSKA
  • Publication number: 20220251082
    Abstract: The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 11, 2022
    Applicant: RYVU THERAPEUTICS S.A.
    Inventors: Magdalena Izabela ZAWADZKA, Luigi Piero STASI, Maciej Krzysztof ROGACKI, Grzegorz Wojciech CWIERTNIA, Lukasz Piotr DUDEK, Monika Patrycja DOBRZANSKA, Grzegorz Witold TOPOLNICKI, Agnieszka Justyna GIBAS, Anna RAJDA, Sylwia SUDOL, Karolina Maria GLUZA, Charles-Henry FABRITIUS
  • Publication number: 20210198233
    Abstract: Compounds of the formula I in which R1 denotes A, Ar, Cyc, Het, COA or CN, R2 denotes SO2A, SOA, SA, SO2NHA, SO2NA2, S(?NH,?O)A, S(?NH)2A, NO2, Hal, CN, A, Het1, COOH or COOA, R3 denotes H or Hal, R4 denotes H or Hal, n denotes 1, 2 or 3, A denotes unbranched or branched alkyl having 1-6 C-atoms, Cyc denotes cyclic alkyl with 3 to 7 C-atoms, Ar denotes phenyl, Het denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, Het1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, and Hal denotes F, Cl, Br, or I, are inhibitors of HIF-2?, and can be employed for the treatment of diseases such as cancer.
    Type: Application
    Filed: May 15, 2019
    Publication date: July 1, 2021
    Applicants: Merck Patent GmbH, Ryvu Therapeutics S.A.
    Inventors: Matthias Leiendecker, Hans-Peter Buchstaller
  • Publication number: 20200369665
    Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers, isotopologues, or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer, isotopologues, or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: June 29, 2018
    Publication date: November 26, 2020
    Applicant: RYVU THERAPEUTICS S.A.
    Inventors: Aneta BOBOWSKA (NÉE WITKOWSKA), Michal GALEZOWSKI, Mateusz NOWAK, Claude COMMANDEUR, Joanna SZEREMETA-SPISAK, Marcin NOWOGRODZKI, Alicja OBARA, Anna DZIELAK, Iwona LOZINSKA, Marcelina DUDEK (NÉE SEDLAK), Anita ` JANIGA, Jacek REUS, Marek WRONOWSKI, Magdalena ZASTAWNA, Adam RADZIMIERSKI, Mateusz SWIRSKI, Julian ZACHMANN, Charles-Henry FABRITIUS, Roderick Alan PORTER, Joanna FOGT